Biosimilars and Regulatory Authorities
نویسندگان
چکیده
منابع مشابه
European regulatory authorities and pediatric labeling.
Ethical Considerations Children should not be given medicines that have not been evaluated adequately for use in that age group. There is a responsibility, shared by applicants and the appropriate authorities, to ensure that children have timely access to safe and effective medicines that have accurate, scientifically justified prescribing information. Applicants are encouraged to investigate t...
متن کاملConflict of interest and regulatory authorities.
164 March 2015, Vol. 105, No. 3 Conflict of interest and regulatory authorities To the Editor: Parrish and Blockman[1] make excellent points about conflict of interest (COI), particularly in the context of ‘medical leadership’. As key opinion leaders themselves (both are members of the National Essential Medicines List Committee (2013 2015), as is the second signatory to this letter – the term ...
متن کاملBiosimilars: a regulatory perspective from America
Biosimilars are protein products that are sufficiently similar to a biopharmaceutical already approved by a regulatory agency. Several biotechnology companies and generic drug manufacturers in Asia and Europe are developing biosimilars of tumor necrosis factor inhibitors and rituximab. A biosimilar etanercept is already being marketed in Colombia and China. In the US, several natural source pro...
متن کاملRegulatory guidelines for biosimilars in Malaysia.
The biosimilars sector continues to attract huge interest and controversy. Biosimilars are new biopharmaceuticals that are "similar" but not identical to the innovator product. Characteristics of biopharmaceuticals are closely related to the manufacturing process, which implies that the products cannot be exactly duplicated. Minuscule differences in the product's structure and manufacturing pro...
متن کاملBiosimilars: Key regulatory considerations and similarity assessment tools
A biosimilar drug is defined in the US Food and Drug Administration (FDA) guidance document as a biopharmaceutical that is highly similar to an already licensed biologic product (referred to as the reference product) notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences in purity, potency, and safety between the two prod...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephron Clinical Practice
سال: 2011
ISSN: 1660-2110,1660-2110
DOI: 10.1159/000319640